NASDAQ NMS - GLOBAL MARKET · AKTS
+0.29% · +$0.0700 · Vol 226.4K
Market closed · last close 4:00 PM ET · price as of 16:04:06 ET
Aktis Oncology Inc

Aktis Oncology Inc

Biotechnology
$24.07
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
AKTS
Aktis Oncology Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

61/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is AKTS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading AKTS catalysts
About Aktis Oncology Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2026
Employees
79
Country
US

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$24.33
Day high
$25.00
Day low
$24.00
Previous close
$24.00
52W high
$32.23
-25.32% from high
52W low
$15.19
52% of range
Market cap
$90.2M
EPS
$-1.1200
Beta
0.95
Shares out
55.6M
Volume
226.4K
0.80× rel vol
Avg volume
283.7K
VWAP
$24.35
Price history computed in-house
1W
-2.63%
1M
+0.75%
3M
+16.96%
SMA 50 $25.20 · below
SMA 200 Not reported · Not reported
52W position 52%

AKTS overview

Veridion Score
61
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around AKTS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading AKTS Form 4 filings
Public disclosures

Congress activity in AKTS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for AKTS in the cached public ledger.

Federal contracts

AKTS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AKTS in this window.
Lobbying spend

AKTS lobbying filings, year to date.

Registered lobbying filings matched to Aktis Oncology Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AKTS in this window.
Loading news for AKTS
Analyst ratings
Sovereign unlock shows live analyst consensus for AKTS.
Options
Sovereign unlock shows live options positioning for AKTS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.